Table 1 Demographics and clinical data for MS participants

From: Durable T cell immunity to COVID-19 vaccines in MS patients on B cell depletion therapy

 

Columbia, UPitt (Figs. 1–3)

All Centers (Fig. 4)

 

BCD

non-BCD

pvalue

BCD

non-BCD

p value

Donors, n

43

58

 

119

97

 

Samples collected, n

49

67

 

161

120

 

Age, mean years ± SD (range)a

44.4 ± 14.6 (24–73)

52.8 ± 11.6 (26–78)

0.0018

44.4 ± 11.7 (24–73)

52.3 ± 11.1 (26–78)

<0.0001

Time post-vaccination, mean days ± SD (range)a

92.3 ± 83.9 (4–383)

117.1 ± 95.2 (6–483)

0.2653

50.2 ± 65.3 (3–383)

83.7 ± 94.2 (6–483)

0.0001

Female Sex, n donors (%)

28 (65.1)

48 (82.8)

0.0614

82 (68.3)

81 (83.5)

0.0168

Ethnicity, n donors (%)b

  

0.1968

   

 Non-Hispanic/Latino

36 (83.7)

54 (93.1)

 

–

–

 

 Hispanic/Latino

7 (16.3)

4 (6.9)

 

–

–

 

 Unknown

0 (0.0)

0 (0.0)

 

–

–

 

Race, n donors (%)b

  

0.8117

   

 Black/African American

6 (14.0)

9 (15.5)

 

–

–

 

 Asian

1 (2.3)

2 (3.5)

 

–

–

 

 Caucasian

33 (76.7)

46 (79.3)

 

–

–

 

 Native American

3 (7.0)

0 (0.0)

 

–

–

 

 Unknown

0 (0.0)

1 (1.7)

 

–

–

 

Vaccine Type, n samples (%)b

  

0.4264

  

0.1185

 BNT162b2

35 (71.4)

42 (62.7)

 

117 (72.7)

76 (63.4)

 

 mRNA-1273

14 (28.6)

25 (37.3)

 

44 (27.3)

43 (35.8)

 

 Unknown

0 (0)

0 (0)

 

0 (0)

1 (0.8)

 

Dose Number, n samplesb

     

0.354

 2

49 (100)

67 (100)

1.000

128 (79.5)

101 (84.2)

 

 3

0 (0)

0 (0)

 

33 (20.5)

19 (15.8)

 

aCD20 Drug, n donors (%)

 Rituximab

16 (37.2)

–

 

34 (28.6)

–

 

 Ocrelizumab

24 (55.8)

–

 

71 (59.7)

–

 

 Ofatumumab

3 (7.0)

–

 

14 (11.7)

–

 

Other Therapy, n donors (%)

 Cladribine

–

2 (3.5)

 

–

2 (2.1)

 

 Dimethyl Fumarate

–

9 (15.5)

 

–

14 (14.4)

 

 Diroximel Fumarate

–

1 (1.7)

 

–

1 (1.0)

 

 Fingolimod

–

1 (1.7)

 

–

9 (9.3)

 

 Glatiramer Acetate

–

8 (13.8)

 

–

16 (16.5)

 

 Interferon beta-1a

–

4 (6.9)

 

–

5 (5.1)

 

 Interferon beta-1b

–

0 (0)

 

–

1 (1.0)

 

 Natalizumab

–

13 (22.4)

 

–

19 (19.6)

 

 Siponimod

–

0 (0)

 

–

2 (2.1)

 

 Teriflunomide

–

6 (10.4)

 

–

6 (6.2)

 

 None

–

14 (24.1)

 

–

22 (22.7)

 

Anti-Nucleocapsid Antibody positivity, n donors (%)

0 (0)

0 (0)

 

–

–

 
  1. aStatistical comparison of demographics performed on continuous variables by Mann-Whitney U-test.
  2. bStatistical comparison of categorical variables performed using Fisher’s Exact test; comparison within race was performed between White and non-White subjects.
Back to article page